Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital
Abstract
:1. Introduction
2. Methods
- Analysis: process mapping (“as is”), goals assessment, identification of priorities and key processes, and creation of the team.
- Planning: identification of gaps and critical points and definition of the most relevant changes.
- Action: change implementation, definition of key performance indicators, and development of a data collection method.
- Monitoring: control and plan of future improvements and integration with the management control process.
3. Results
3.1. Analysis and Planning
3.2. Action and Monitoring
- Alignment between the professionals and the design of a dedicated, transversal bone health pathway to be applied for all BC patients undergoing hormonal adjuvant therapies, in line with Note 79 (regarding the correct therapy definition) for personalized patient management and care.
- Identification and integration of a bone specialist from the tumor board phase, to define every therapeutic strategy for each patient and evaluate the treatment of bone loss.
- Introduction of a case manager (nurse) as a pivotal figure for interprofessional coordination, supporting therapy prescription and follow-up, as well as patient education.
- Training the health professionals and administrative staff involved in activity ownership and timing, to select the best care treatment and facilitate the organizational workflow.
- (a)
- If the patient has not been evaluated, the case manager schedules an appointment within 30 days of the prescription of adjuvant endocrine treatment.
- (b)
- If the evaluation is already present, the case manager assesses whether the examinations are recent and have them repeated if necessary.
- (c)
- If no such evaluation is present, the case manager prescribes DXA of the spine and femur and a blood panel for bone metabolism assessment.
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Wilkinson, L.; Gathani, T. Understanding breast cancer as a global health concern. Br. J. Radiol. 2021, 95, 20211033. [Google Scholar] [CrossRef] [PubMed]
- Associazione Italiana di Oncologia Medica (AIOM). I Numeri del Cancro in Italia 2022. Available online: https://www.aiom.it/wp-content/uploads/2022/12/2022_AIOM_NDC-web.pdf (accessed on 17 July 2023).
- Italian Ministry of Health. Il Tumore della Mammella. 2023. Available online: https://www.salute.gov.it/portale/tumori/dettaglioContenutiTumori.jsp?lingua=italiano&id=5538&area=tumori&menu=vuoto (accessed on 17 July 2023).
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Sleightholm, R.; Neilsen, B.K.; Elkhatib, S.; Flores, L.; Dukkipati, S.; Zhao, R.; Choudhury, S.; Gardner, B.; Carmichael, J.; Smith, L.; et al. Percentage of Hormone Receptor Positivity in Breast Cancer Provides Prognostic Value: A Single-Institute Study. J. Clin. Med. Res. 2021, 13, 9–19. [Google Scholar] [CrossRef] [PubMed]
- Owens, D.K.; Davidson, K.W.; Krist, A.H.; Barry, M.J.; Cabana, M.; Caughey, A.B.; Doubeni, C.A.; Epling, J.W.; Kubik, M.; Landefeld, C.S. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2019, 322, 857–867. [Google Scholar] [CrossRef] [PubMed]
- Nourmoussavi, M.; Pansegrau, G.; Popesku, J.; Hammond, G.L.; Kwon, J.S.; Carey, M.S. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. Cancer Treat. Rev. 2017, 55, 26–35. [Google Scholar] [CrossRef] [PubMed]
- Hadji, P.; Aapro, M.S.; Body, J.J.; Gnant, M.; Brandi, M.L.; Reginster, J.Y.; Zillikens, M.C.; Glüer, C.-C.; de Villiers, T.; Baber, R.; et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J. Bone Oncol. 2017, 7, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Blake, G.M.; Fogelman, I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad. Med. J. 2007, 83, 509–517. [Google Scholar] [CrossRef] [PubMed]
- Glüer, C.C. 30 years of DXA technology innovations. Bone 2017, 104, 7–12. [Google Scholar] [CrossRef] [PubMed]
- Messina, C.; Albano, D.; Gitto, S.; Tofanelli, L.; Bazzocchi, A.; Ulivieri, F.M.; Guglielmi, G.; Sconfienza, L.M. Body composition with dual energy X-ray absorptiometry: From basics to new tools. Quant. Imaging Med. Surg. 2020, 10, 1687–1698. [Google Scholar] [CrossRef]
- Saarto, T.; Vehmanen, L.; Elomaa, I.; Välimäki, M.; Mäkelä, P.; Blomqvist, C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br. J. Cancer 2001, 84, 1047–1051. [Google Scholar] [CrossRef]
- Confavreux, C.B.; Fontana, A.; Guastalla, J.P.; Munoz, F.; Brun, J.; Delmas, P. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41, 346–352. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Cuzick, J.; Edwards, R.; Blake, J.; Truscott, R.; Coleman, R.; Eastell, R.; Howell, A. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the international breast cancer intervention study (IBIS-II). Breast Cancer Res. Treat. 2007, 106, S9. [Google Scholar] [CrossRef]
- Ellis, G.K.; Bone, H.G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 2008, 26, 4875–4882. [Google Scholar] [CrossRef] [PubMed]
- Greenspan, S.L.; Brufsky, A.; Lembersky, B.C.; Bhattacharya, R.; Vujevich, K.T.; Perera, S.; Sereika, S.M.; Vogel, V.G. Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial. J. Clin. Oncol. 2008, 26, 2644–2652. [Google Scholar] [CrossRef] [PubMed]
- Lester, J.E.; Dodwell, D.; Purohit, O.P.; Gutcher, S.A.; Ellis, S.P.; Thorpe, R.; Horsman, J.M.; Brown, J.E.; Hannon, R.A.; Coleman, R.E. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 2008, 14, 6336–6342. [Google Scholar] [CrossRef] [PubMed]
- Hines, S.L.; Mincey, B.; Dentchev, T.; Sloan, J.A.; Perez, E.A.; Johnson, D.B.; Schaefer, P.L.; Alberts, S.; Liu, H.; Kahanic, S.; et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res. Treat. 2009, 117, 603–609. [Google Scholar] [CrossRef]
- Llombart, A.; Frassoldati, A.; Paija, O.; Sleeboom, H.P.; Jerusalem, G.; Mebis, J. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. In Proceedings of the American Society of Clinical Oncology 2009 Breast Cancer Symposium, San Francisco, CA, USA, 8–10 October 2009; Abstract 213. [Google Scholar]
- van Poznak, C.; Hannon, R.A.; Mackey, J.R.; Campone, M.; Apffelstaedt, J.P.; Clack, G.; Barlow, D.; Makris, A.; Eastell, R. Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J. Clin. Oncol. 2010, 28, 967–975. [Google Scholar] [CrossRef]
- Chlebowski, R.T.; Chen, Z.; Cauley, J.A.; Anderson, G.; Rodabough, R.J.; McTiernan, A.; Lane, D.S.; Manson, J.E.; Snetselaar, L.; Yasmeen, S.; et al. Oral Bisphosphonate use and breast cancer incidence in postmenopausal women. J. Clin. Oncol. 2010, 28, 3582–3590. [Google Scholar] [CrossRef]
- Associazione Italiana di Oncologia Medica (AIOM). Linee Guida. Neoplasie della Mammella. 2020. Available online: https://www.aiom.it/wp-content/uploads/2020/10/2020_LG_AIOM_NeoplasieMammella.pdf (accessed on 17 July 2023).
- Gnant, M.; Pfeiler, G.; Dubsky, P.C.; Hubalek, M.; Greil, R.; Jakesz, R.; Wette, V.; Balic, M.; Haslbauer, F.; Melbinger, E.; et al. Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015, 386, 433–443. [Google Scholar] [CrossRef]
- Gnant, M.; Pfeiler, G.; Steger, G.G.; Egle, D.; Greil, R.; Fitzal, F.; Wette, V.; Balic, M.; Haslbauer, F.; Melbinger-Zeinitzer, E.; et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): Disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019, 20, 339–351. [Google Scholar] [CrossRef]
- Agenzia Italiana del Farmaco (AIFA). Nota 79. Farmaci a Carico SSN Inclusi Nella Nota 79: Alendronato, Bazedoxifene, Denosumab, Ibandronato, Raloxifene, Risedronato, Romosozumab, Teriparatide, Zoledronato. 2017. Available online: https://www.aifa.gov.it/nota-79 (accessed on 17 July 2023).
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet 2015, 386, 1353–1361. [Google Scholar] [CrossRef]
- Coleman, R.; Finkelstein, D.; Barrios, C.H.; Martin, M.; Iwata, H.; Glaspy, J.A.; Zhou, Y.; Jandial, D.; Chan, A. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. J. Clin. Oncol. 2018, 38, 4569–4580. [Google Scholar] [CrossRef]
- Perrone, F.; De Laurentiis, M.; de Placido, S.; Orditura, M.; Cinieri, S.; Riccardi, F.; Ribecco, A.; Putzu, C.; Del Mastro, L.; Rossi, E.; et al. The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid. Ann. Oncol. 2018, 29, viii704. [Google Scholar] [CrossRef]
- Recine, F.; Bongiovanni, A.; Foca, F.; Mercatali, L.; Fausti, V.; Calpona, S.; Riva, N.; De Vita, A.; Liverani, C.; Spadazzi, C.; et al. BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study). J. Clin. Med. 2019, 8, 1894. [Google Scholar] [CrossRef]
- Nimmesgern, E.; Benediktsson, I.; Norstedt, I. Personalized Medicine in Europe. Clin. Transl. Sci. 2017, 10, 61–63. [Google Scholar] [CrossRef]
- De Maria Marchiano, R.; Di Sante, G.; Piro, G.; Carbone, C.; Tortora, G.; Boldrini, L.; Pietragalla, A.; Daniele, G.; Tredicine, M.; Cesario, A.; et al. Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go. J. Pers. Med. 2021, 11, 216. [Google Scholar] [CrossRef]
- Nero, C.; Duranti, S.; Giacomini, F.; Minucci, A.; Giacò, L.; Piermattei, A.; Genuardi, M.; Pasciuto, T.; Urbani, A.; Daniele, G.; et al. Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. J. Pers. Med. 2022, 12, 1746. [Google Scholar] [CrossRef]
- Davenport, H.T. Process Innovation: Reengineering Work through Information Technology; Harvard Business Press: Boston, MA, USA, 1993. [Google Scholar]
- Villa, S. Operations Management for Healthcare Organizations: Theory, Models and Tools; Routledge: Abingdon-on-Thames, UK, 2021. [Google Scholar]
- Mwandala, T. Roles, Training, and Qualifications of a Case Manager in the Canadian Health Care Industry: A Narrative Review. Prof. Case Manag. 2021, 26, 27–33. [Google Scholar] [CrossRef] [PubMed]
- Palese, A.; Gonella, S.; Brugnolli, A.; Mansutti, I.; Saiani, L.; Terzoni, S.; Destrebecq, A.; Zannini, L.; Grassetti, L.; Dimonte, V. Nursing students’ interprofessional educational experiences in the clinical context: Findings from an Italian cross-sectional study. BMJ Open 2019, 9, e025575. [Google Scholar] [CrossRef] [PubMed]
- Tarantino, U.; Iolascon, G.; Cianferotti, L.; Masi, L.; Marcucci, G.; Giusti, F.; Marini, F.; Parri, S.; Feola, M.; Rao, C.; et al. Clinical guidelines for the prevention and treatment of osteoporosis: Summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. J. Orthop. Traumatol. 2019, 18, 3–36. [Google Scholar] [CrossRef]
- PRB. Countries with the Oldest Populations in the World. 2022. Available online: https://www.prb.org/resources/countries-with-the-oldest-populations-in-the-world/ (accessed on 17 July 2023).
- Cauley, J.A. Public health impact of osteoporosis. J. Gerontol. A Biol. Sci. Med. Sci. 2013, 68, 1243–1251. [Google Scholar] [CrossRef] [PubMed]
- Cesario, A.; Simone, I.; Paris, I.; Boldrini, L.; Orlandi, A.; Franceschini, G.; Lococo, F.; Bria, E.; Magno, S.; Mulè, A.; et al. Development of a Digital Research Assistant for the Management of Patients’ Enrollment in Oncology Clinical Trials within a Research Hospital. J. Pers. Med. 2021, 11, 244. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Amar, I.D.; Franceschini, G.; Nero, C.; Pasqua, I.; Paris, I.; Orlandi, A.; Gori, S.; Fabi, A.; Garganese, G.; Scambia, G.; et al. Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital. J. Pers. Med. 2024, 14, 371. https://doi.org/10.3390/jpm14040371
Amar ID, Franceschini G, Nero C, Pasqua I, Paris I, Orlandi A, Gori S, Fabi A, Garganese G, Scambia G, et al. Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital. Journal of Personalized Medicine. 2024; 14(4):371. https://doi.org/10.3390/jpm14040371
Chicago/Turabian StyleAmar, Inbal Dona, Gianluca Franceschini, Camilla Nero, Ilaria Pasqua, Ida Paris, Armando Orlandi, Stefania Gori, Alessandra Fabi, Giorgia Garganese, Giovanni Scambia, and et al. 2024. "Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital" Journal of Personalized Medicine 14, no. 4: 371. https://doi.org/10.3390/jpm14040371